Navigation Links
PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday
Date:10/9/2007

hed.

The PARI LC PLUS and the PRONEB Ultra are the most frequently used compressor-based nebulizer system for new nebulized medications in clinical development.

About Perforomist Inhalation Solution Indication

Perforomist Inhalation Solution is indicated for the long-term, twice-daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.

Important Safety Information

Perforomist Inhalation Solution belongs to a class of medications known as long-acting beta2-adrenergic agonists (LABAs). LABAs may increase the risk of asthma-related death. Data from a large placebo-controlled US study comparing the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a LABA), the active ingredient in Perforomist Inhalation Solution.

Perforomist Inhalation Solution should not be used in patients with acutely deteriorating COPD or to treat acute symptoms. Acute symptoms should be treated with fast-acting rescue inhalers. Perforomist Inhalation Solution should not be used with other medications containing LABAs. Do not use more than one nebule twice daily. Perforomist Inhalation Solution should be used with caution in patients with cardiovascular disorders. Perforomist Inhalation Solution is not a substitute for inhaled or oral corticosteroids. The safety and efficacy of Perforomist Inhalation Solution in asthma has not been established.

In COPD clinical trials, the most common adverse events reported with Perforomist Inhalation Solution were diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, and insomnia. Please see full Prescribing Information, including Boxed Warning, at http://www.perf
'/>"/>

SOURCE PARI Respiratory Equipment, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. High-Throughput System Generates Ultra-Pure PCR Products Suitable for All Applications
2. Efficient Recovery of Ultrapure Plasmid DNA
3. Ultra-Fast Purification of Small Nucleic Acids
4. Inactivation of Contaminating Templates in PCR Using High Intensity Ultraviolet Light
5. Analysis of urine and seawater samples by ultrasonic nebulization with a high resolution ICP spectrometer
6. REPLI-g UltraFast Mini Kit
7. GE Healthcare leads compact ultrasound market
8. GE introduces compact ultrasound system for women
9. pFB-ERV: Retroviral Delivery of the Ecdysone Receptor Proteins
10. High-Titer Retroviral Vectors for Gene Delivery
11. Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and ... and commercializing proven cancer therapies in new orphan ... the 106th Annual Meeting of the American ... on the potential for its lead product candidate ...
(Date:4/20/2015)... 2015  Ardelyx, Inc. (NASDAQ: ARDX ), ... and metabolic diseases, today announced that Annalisa ... Board of Directors. Dr. Jenkins brings a wealth ... built and led teams advancing programs from scientific ... healthcare systems globally. "Annalisa brings ...
(Date:4/20/2015)... , April 20, 2015  "Everybody is affected ... do to patients is frankly brutal. We,ve got to ... a cancer ward, or witnessed a loved one or ... witnessed firsthand the devastation chemotherapy and other treatments cause ... people want to give up and succumb to the ...
(Date:4/20/2015)... Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products ... the fourth quarter and full year ended December 31, ... the fourth quarter 2013) , Quarterly sales were ... million in the prior year period. Excluding revenue recognized ... $0.1 million in the fourth quarter of 2014 and ...
Breaking Biology Technology:DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18
... 2011 BioSpecifics Technologies Corp. (NASDAQ: BSTC ... products, today announced that there will be three separate ... for the treatment of patients suffering from Dupuytren,s contracture ... Societies for Surgery of the Hand Meeting to be ...
... Children at Paterson Public School No. 5 received ... more than 200 volunteers from Roche, New Jersey Community ... from non-profit KaBOOM!. The new playground provides the 1,300-plus ... well as children living in the neighborhood with a ...
... JOSE, Calif., May 18, 2011 Oclaro, Inc. (NASDAQ: ... communications and laser solutions, today announced that its 9xx ... Pantec Biosolutions, the leading provider of epidermal medical applications, ... Epidermal System) platform. This cutting-edge new laser platform represents ...
Cached Biology Technology:BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting 2BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting 3BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting 4Designed by Kids, Built by Volunteers: Roche, New Jersey Community Development Corporation, and KaBOOM! Build New Playground in Just One Day for Paterson Public School Children 2Designed by Kids, Built by Volunteers: Roche, New Jersey Community Development Corporation, and KaBOOM! Build New Playground in Just One Day for Paterson Public School Children 3Designed by Kids, Built by Volunteers: Roche, New Jersey Community Development Corporation, and KaBOOM! Build New Playground in Just One Day for Paterson Public School Children 4Pantec Biosolutions Selects Oclaro Laser Diode Bars for Transdermal Drug Delivery and Tissue Ablation Systems 2Pantec Biosolutions Selects Oclaro Laser Diode Bars for Transdermal Drug Delivery and Tissue Ablation Systems 3Pantec Biosolutions Selects Oclaro Laser Diode Bars for Transdermal Drug Delivery and Tissue Ablation Systems 4
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... more corals and fish generate predictably greater levels of ... has important implications for understanding the behaviour of young ... environmental health by listening to reefs. Contrary to ... places, with fish and invertebrates producing clicks and grunts ...
... SALT LAKE CITYResearchers at Huntsman Cancer Institute (HCI) at the ... necessary for the maintenance and repair of the cell,s cytoskeleton, ... of the cell. The research has implications for cancer, as ... often associated with disease. The research was published in the ...
... failure of the Deepwater Horizon oil well last spring, nearly ... of Mexico to contain the spill. While preliminary reports suggest ... effect of such a massive volume of dispersant on ecosystems, ... a University at Buffalo researcher with expertise in how the ...
Cached Biology News:Taking the pulse of coral reefs 2Study offers first explanation of how cells rapidly repair and maintain structure 2A less toxic, more efficient dispersant is scientist's goal 2
NovaScreen offers cell biology, cell culture and molecular biology services for companies who lack a cell culture facility....
Cells are grown in triple flasks or roller bottles. Viability and growth data are generated from a parallel representative culture....
... essential for hunting and analyzing the ... as EST sequencing projects, microarrays, functional ... not well suited for the normalization ... kit, though, is specially developed for ...
... Tecan has 20 years of expertise ... (ELISA), and still offers the most powerful ... manages up to 40 000 in-microplate tests ... The integration of different modules (such as ...
Biology Products: